Literature DB >> 20335269

Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2.

Qingbiao Huang1, Grazyna D Szklarz.   

Abstract

Human CYP1A2 is an important drug-metabolizing enzyme, similar in sequence to CYP1A1 but with distinct substrate specificity. We have previously shown that residue 382 affected CYP1A1 and CYP1A2 specificities with alkoxyresorufins. To determine whether this residue is also important for the metabolism of other substrates, we have investigated phenacetin oxidation by single (T124S, T223N, V227G, N312L, and L382V) and multiple (L382V/T223N, L382V/N312L, L382V/T223N/N312L, and L382V/T124S/N312L) mutants of CYP1A2. The enzymes were expressed in Escherichia coli and purified. All the CYP1A2 mutants that contained the L382V substitution displayed much higher activities than the wild-type enzyme, with k(cat) values 3-fold higher, in contrast to other mutants, for which k(cat) decreased. Likewise, a significant increase in specificity, expressed as the k(cat)/K(m) ratio, was observed for the mutants containing the L382V substitution. The efficiency of coupling of reducing equivalents to acetaminophen formation was decreased for all the single mutants except L382V, for which the coupling increased. This effect was also observed with multiple CYP1A2 mutants containing the L382V substitution. Low activities of the four other single mutants were likely caused by dramatically increased uncoupling to water. In contrast, the increase in activity of the L382V-containing mutants resulted from decreased water formation. This finding is consistent with molecular dynamics results, which showed decreased phenacetin mobility leading to increased product formation. The results of these studies confirm the importance of residue 382 in CYP1A2-catalyzed oxidations and show that a single residue substitution can dramatically affect enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335269      PMCID: PMC2908983          DOI: 10.1124/dmd.109.030767

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

1.  A 175-psec molecular dynamics simulation of camphor-bound cytochrome P-450cam.

Authors:  M D Paulsen; R L Ornstein
Journal:  Proteins       Date:  1991

2.  Probing the active site of cytochrome P450 2B1: metabolism of 7-alkoxycoumarins by the wild type and five site-directed mutants.

Authors:  Y Kobayashi; X Fang; G D Szklarz; J R Halpert
Journal:  Biochemistry       Date:  1998-05-12       Impact factor: 3.162

Review 3.  Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and compact-3D.

Authors:  D F Lewis; H Moereels; B G Lake; C Ioannides; D V Parke
Journal:  Drug Metab Rev       Date:  1994       Impact factor: 4.518

4.  Stoichiometry of 7-ethoxycoumarin metabolism by cytochrome P450 2B1 wild-type and five active-site mutants.

Authors:  X Fang; Y Kobayashi; J R Halpert
Journal:  FEBS Lett       Date:  1997-10-13       Impact factor: 4.124

5.  Molecular basis for a functionally unique cytochrome P450IIB1 variant.

Authors:  K M Kedzie; C A Balfour; G Y Escobar; S W Grimm; Y A He; D J Pepperl; J W Regan; J C Stevens; J R Halpert
Journal:  J Biol Chem       Date:  1991-11-25       Impact factor: 5.157

6.  Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.

Authors:  L L von Moltke; D J Greenblatt; S X Duan; J Schmider; L Kudchadker; S M Fogelman; J S Harmatz; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

7.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

8.  NMR studies of substrate binding to cytochrome P450 BM3: comparisons to cytochrome P450 cam.

Authors:  S Modi; W U Primrose; J M Boyle; C F Gibson; L Y Lian; G C Roberts
Journal:  Biochemistry       Date:  1995-07-18       Impact factor: 3.162

9.  Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver.

Authors:  M D Burke; S Thompson; R J Weaver; C R Wolf; R T Mayer
Journal:  Biochem Pharmacol       Date:  1994-08-30       Impact factor: 5.858

10.  Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse.

Authors:  P V Nerurkar; S S Park; P E Thomas; R W Nims; R A Lubet
Journal:  Biochem Pharmacol       Date:  1993-09-01       Impact factor: 5.858

View more
  8 in total

1.  Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism.

Authors:  Qingbiao Huang; Rahul S Deshmukh; Spencer S Ericksen; Youbin Tu; Grazyna D Szklarz
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

2.  Simultaneous measurement of CYP1A2 activity, regioselectivity, and coupling: Implications for environmental sensitivity of enzyme-substrate binding.

Authors:  Matthew J Traylor; Jack Chai; Douglas S Clark
Journal:  Arch Biochem Biophys       Date:  2010-10-08       Impact factor: 4.013

3.  Differential oxidation of two thiophene-containing regioisomers to reactive metabolites by cytochrome P450 2C9.

Authors:  Peter M Rademacher; Caleb M Woods; Qingbiao Huang; Grazyna D Szklarz; Sidney D Nelson
Journal:  Chem Res Toxicol       Date:  2012-03-14       Impact factor: 3.739

4.  Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism.

Authors:  Agnes A Walsh; Grazyna D Szklarz; Emily E Scott
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

5.  Structure-Function Analysis of Mammalian CYP2B Enzymes Using 7-Substituted Coumarin Derivatives as Probes: Utility of Crystal Structures and Molecular Modeling in Understanding Xenobiotic Metabolism.

Authors:  Manish B Shah; Jingbao Liu; Lu Huo; Qinghai Zhang; M Denise Dearing; P Ross Wilderman; Grazyna D Szklarz; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2016-01-29       Impact factor: 4.436

6.  Increased Phenacetin Oxidation upon the L382V Substitution in Cytochrome P450 1A2 is Associated with Altered Substrate Binding Orientation.

Authors:  Qingbiao Huang; Grazyna D Szklarz
Journal:  Int J Mol Sci       Date:  2018-05-25       Impact factor: 5.923

7.  Multiple CH/π Interactions Maintain the Binding of Aflatoxin B₁ in the Active Cavity of Human Cytochrome P450 1A2.

Authors:  Jun Wu; Sisi Zhu; Yunbo Wu; Tianqing Jiang; Lingling Wang; Jun Jiang; Jikai Wen; Yiqun Deng
Journal:  Toxins (Basel)       Date:  2019-03-12       Impact factor: 4.546

Review 8.  Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.

Authors:  Zbigniew Dutkiewicz; Renata Mikstacka
Journal:  Bioinorg Chem Appl       Date:  2018-07-25       Impact factor: 7.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.